MedTrace Logo

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

NCT05055258 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

Conditions

  • Angioedema, Hereditary, Types I and II

Interventions

DRUG

KVD824

KVD824 300 mg Modified-Release Tablets

DRUG

Placebo to KVD824

Placebo to KVD824 300 mg Modified-Release Tablets

Sponsors & Collaborators

  • KalVista Pharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • Study Director · KalVista Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2022-10-27
Completion
2022-10-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • New Zealand
  • North Macedonia
  • Puerto Rico
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05055258 on ClinicalTrials.gov